Astellas Pharma Valuation
| YPH Stock | EUR 9.50 0.20 2.15% |
At this time, the firm appears to be overvalued. Astellas Pharma shows a prevailing Real Value of €8.4 per share. The current price of the firm is €9.5. Our model approximates the value of Astellas Pharma from analyzing the firm fundamentals such as Return On Equity of 0.0898, current valuation of 24.85 B, and Profit Margin of 0.09 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Astellas Pharma's price fluctuation is somewhat reliable at this time. Calculation of the real value of Astellas Pharma is based on 3 months time horizon. Increasing Astellas Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Astellas stock is determined by what a typical buyer is willing to pay for full or partial control of Astellas Pharma. Since Astellas Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Astellas Stock. However, Astellas Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.5 | Real 8.4 | Hype 9.5 | Naive 9.48 |
The real value of Astellas Stock, also known as its intrinsic value, is the underlying worth of Astellas Pharma Company, which is reflected in its stock price. It is based on Astellas Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Astellas Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Astellas Pharma helps investors to forecast how Astellas stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Astellas Pharma more accurately as focusing exclusively on Astellas Pharma's fundamentals will not take into account other important factors: Astellas Pharma Total Value Analysis
Astellas Pharma is at this time estimated to have takeover price of 24.85 B with market capitalization of 23.71 B, debt of 308 M, and cash on hands of 305.99 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Astellas Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
24.85 B | 23.71 B | 308 M | 305.99 B |
Astellas Pharma Investor Information
About 50.0% of the company outstanding shares are owned by institutional investors. The book value of Astellas Pharma was at this time reported as 847.56. The company last dividend was issued on the 30th of March 2023. Astellas Pharma had 5:1 split on the 27th of March 2014. Based on the key measurements obtained from Astellas Pharma's financial statements, Astellas Pharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Astellas Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Astellas Pharma has an asset utilization ratio of 55.57 percent. This implies that the Company is making €0.56 for each dollar of assets. An increasing asset utilization means that Astellas Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Astellas Pharma Ownership Allocation
Astellas Pharma holds a total of 1.83 Billion outstanding shares. Over half of Astellas Pharma's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Astellas Pharma. Please watch out for any change in the institutional holdings of Astellas Pharma as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Astellas Pharma Profitability Analysis
The company reported the revenue of 1.3 T. Net Income was 124.09 B with profit before overhead, payroll, taxes, and interest of 1.04 T.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Astellas Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Astellas Pharma and how it compares across the competition.
About Astellas Pharma Valuation
The stock valuation mechanism determines Astellas Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Astellas Pharma. We calculate exposure to Astellas Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Astellas Pharma's related companies.Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15455 people.
8 Steps to conduct Astellas Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Astellas Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Astellas Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Astellas Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Astellas Pharma's revenue streams: Identify Astellas Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Astellas Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Astellas Pharma's growth potential: Evaluate Astellas Pharma's management, business model, and growth potential.
- Determine Astellas Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Astellas Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Astellas Stock analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |